Gujarat Themis Biosyn Limited has informed the Exchange regarding Change in Director(s) of the company.
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Themis Biosyn's board approved unaudited Q1 FY26 results showing total income of Rs 361.47 crore and net profit of Rs 90.62 lakh, down from Rs 132.36 lakh in the same quarter last year — a roughly 31% YoY drop in profit. The board has appointed Mr. Nihar Parikh (former CEO of ZCL Chemicals/Zandu, now a health-tech venture capital founder) as an Additional Non-Executive Independent Director from August 1, 2025, replacing Mr. Siddharth Kusumgar who steps down on September 20, 2025 after completing his second consecutive term. The company has fixed September 5, 2025 as the record date for the FY25 dividend. Separately, the board confirmed it will not proceed with the earlier proposed merger with Themis Medicare Limited and will instead focus on its core fermentation-based pharma intermediates and API business, where a new state-of-the-art API plant in Vapi commenced commercial production on May 8, 2025.
Weakening Q1 profits and the scrapped merger with Themis Medicare may weigh on near-term sentiment, but the new API plant targeting US and Europe markets and a stable independent director transition are positive longer-term signals. The declared dividend offers some income support to shareholders.